New Drugs Bringing New Challenges to AML: A Brief Review

Yeoh, Zhi Han; Bajel, Ashish; Wei, Andrew H.

doi:10.3390/jpm11101003

Cited by 6 publications

(6 citation statements)

References 75 publications

(107 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several scientific advancements over the last decade have improved our understanding of the genetic diversity of AML and have led to the development of new therapies ( 19 ). The goal of induction chemotherapy treatment in patients with AML is achieving remission and is associated with severe neutropenia and immunosuppression.…”

Section: Discussionmentioning

confidence: 99%

Case report: Invasive fungal infection in a patient with a rare CVID-causing gene (TNFRSF13B) mutation undergoing AML treatment

Tabak

Hyter²,

Yacoub³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a complex diagnosis that puts patients at a higher risk for developing infections, particularly invasive fungal infections (IFI). Mutations in TNFRSF13B have been shown to cause dysfunction in B-cell homeostasis and differentiation, making it a risk factor for developing immunodeficiency syndromes. In this case, a male patient in his 40s presented to our emergency department (ED) with symptoms leading to a diagnosis of AML with concurrent mucormycosis of the lungs and sinuses. Targeted next generation sequencing (NGS) of the patient’s bone marrow showed, among other variants, a loss of function mutation in the TNFRSF13B gene. While most patients present with fungal infections after prolonged periods of neutropenia associated with AML treatment, this case presented with IFI at diagnosis without neutropenia suggesting an immunodeficiency syndrome. The concurrent IFI and AML diagnoses create a delicate balance between treatment of the infection and the malignancy. This case highlights the risk of infection in patients receiving chemotherapy, especially those with unrecognized immunodeficiency syndromes, and emphasizes the importance of NGS for prognosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report: Invasive fungal infection in a patient with a rare CVID-causing gene (TNFRSF13B) mutation undergoing AML treatment

Tabak

Hyter²,

Yacoub³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In recent years, several new therapies for the treatment of AML have appeared. These therapies involve kinase inhibitors (FLT3 inhibitors), IDH1/IDH2 inhibitors, BCL-2 inhibitors, hedgehog inhibitors and others [2][3][4][5][6][7][8][9][10][11][12][13][14][15]. Glasdegib (Figure 1), 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea (previously also known as PF-04449913), was developed by Pfizer for the treatment of AML [16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue

et al. 2022

View full text Add to dashboard Cite

Glasdegib is a recently approved drug for the treatment of acute myeloid leukemia. It is formulated and marketed in monomaleate salt form. In our investigation, we were able to prepare a glasdegib dimaleate form, which could, in theory, exist in double-salt form or as a mixture of salt and co-crystal species. Therefore, the obtained crystals of glasdegib dimaleate were characterized via 15N ssNMR and single-crystal X-ray diffraction, which revealed that the obtained glasdegib dimaleate exists in double-salt form. This is a surprising finding based on the pKa values for glasdegib and maleic acid. Furthermore, we fully characterized the new dimaleate form using thermal analyses (DSC and TGA) and spectroscopy (IR and Raman). Finally, the physicochemical properties, such as solubility and chemical stability, of both forms were determined and compared.

show abstract

“…This Special Issue of the Journal of Personalized Medicine entitled "Targeted therapy in Leukaemia, Lymphoma and Myeloma" contains 10 publications authored by experts working in a diverse range of haematological cancers including B cell non-Hodgkin lymphoma [22][23][24][25], T-cell non-Hodgkin lymphoma [26], Multiple Myeloma [27][28][29], Chronic Lymphocytic Leukaemia [23,25,28], Acute Myeloid Leukaemia [28,30] and Acute Lymphoblastic Leukemia [31].…”

mentioning

confidence: 99%

“…These neoplasms are biologically distinct but share biological features which enable certain agents to be used across a broad range of tumours including BCL2 inhibitors in B cell non-Hodgkin lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia [28,30]; hypomethylating agents in T cell Lymphoma and Acute Myeloid Leukaemia [26,30]; BTK inhibitors in Chronic Lymphocytic Leukaemia and B cell lymphoma [25]; Cereblon-Interacting Small Molecules in Follicular Lymphoma and Myeloma [22,27,29]; and Bispecific antibodies in B cell lymphoma and B Lymphoblastic leukaemia [24,31].…”

mentioning

confidence: 99%